10-K: XBiotech Reports 2025 Losses, Advances Oncology Program

XBiotech Inc. reported a net loss of $45.5 million for fiscal year 2025, driven by increased R&D expenses and executive severance, while highlighting positive oncology clinical trial results and ongoing regulatory discussions for Natrunix.

Summary

• Reported a net loss of $45.5 million for the fiscal year ended December 31, 2025, compared to a net loss of $38.5 million for the year ended December 31, 2024.
• Research and development (R&D) expenses increased by 26% to $47.4 million in FY2025 from $37.8 million in FY2024.
• General and administrative (G&A) expenses increased by 76% to $8.3 million in FY2025 from $4.7 million in FY2024.
• Cash and cash equivalents decreased to $125.6 million as of December 31, 2025, from $172.7 million as of December 31, 2024.
• The Phase II clinical study for Natrunix in oncology (pancreatic cancer) showed positive preliminary efficacy and safety, including reduced hospitalization, fewer serious adverse events, longer progression-free survival, and less severe diarrhea.
• The rheumatology program for Natrunix was paused due to "widespread improprieties at clinical sites" that rendered the data uninterpretable.
• A Phase I study for Hutrukin, a stroke therapeutic, was completed at the end of 2023, demonstrating safety and tolerability; however, the planned Phase II study is on hold pending regulatory clarity for cancer and arthritis programs.
• John Simard, the Company's Founder, Chairman, and former President and Chief Executive Officer, retired from his CEO role on December 8, 2025, receiving a $17.3 million severance payment and a $4.5 million annual bonus for 2025.
• The company expects to incur significant and increasing operating losses for the foreseeable future and does not anticipate generating any revenue in fiscal year 2026.
• Potential milestone payments of up to $600 million from the 2019 Janssen Transaction remain unearned as of December 31, 2025, and are contingent on Janssen's discretion and regulatory approvals.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for XBiotech, marked by increasing losses, significant cash burn, and a major clinical trial setback in rheumatology, despite some positive oncology data. The reliance on future financing and uncertain milestone payments adds to the negative sentiment.

Positives

• Positive preliminary efficacy and safety results for Natrunix in oncology (pancreatic cancer) Phase II study, showing reduced hospitalization, fewer serious adverse events, longer progression-free survival, and less severe diarrhea.
• Successful completion of Phase I study for Hutrukin (stroke therapy) demonstrating safety and tolerability of high doses.
• The company continues to believe in the potential for Natrunix as a treatment for arthritic diseases despite current setbacks.
• Maintains a pipeline of True Human monoclonal antibodies for inflammatory and infectious diseases, including clinical stage therapeutic for MRSA and preclinical stage therapeutics for C. difficile, shingles, and influenza.
• Operates a state-of-the-art research and manufacturing center on its debt-free 48-acre campus in Austin, Texas.
• Received $1.456 million in other income in 2025, primarily from an Employee Retention Credit and cancellation of a Canada Revenue Agency penalty.
• The company believes its cash and liquid assets of $125.6 million are sufficient to fund operations and meet capital requirements for at least 12 months.

Negatives

• Net loss increased to $45.5 million in FY2025 from $38.5 million in FY2024.
• Cash and cash equivalents decreased by $47.126 million in FY2025, ending at $125.6 million.
• Research and development expenses increased by 26% to $47.4 million in FY2025.
• General and administrative expenses increased by 76% to $8.3 million in FY2025, partly due to executive severance and bonus payments.
• The rheumatology program for Natrunix was halted due to "widespread improprieties at clinical sites" rendering the data uninterpretable, representing a significant clinical setback.
• The Phase II stroke study for Hutrukin is on hold, delaying its development.
• No product revenue has been generated to date, and none is expected in FY2026.
• Milestone payments of up to $600 million from the Janssen Transaction are discretionary and have not been earned, posing uncertainty for future funding.
• Interest income decreased in FY2025 due to lower interest rates and a reduced cash balance.

Risks

• Incurring significant losses during pipeline development and may never sustain profitability.
• Future success is dependent on regulatory approval and commercialization of product candidates, which is uncertain.
• New laws or regulations could impact the ability to receive necessary approvals to successfully market and commercialize product candidates.
• Product candidates may not have favorable results in clinical trials or receive regulatory approval; prior setbacks in the rheumatology program highlight this risk.
• Inability to complete clinical trials on a timely basis, incurring higher costs and delayed development timelines.
• The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• Product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit commercial profile, or result in negative consequences.
• Approved product candidates may not receive coverage and adequate reimbursement from third-party payers.
• Inability to establish an effective sales force and marketing infrastructure or enter into acceptable third-party sales and marketing or licensing arrangements.
• Approved product candidates may not achieve adequate market acceptance for commercial success.
• Substantial competition from other companies that may discover, develop, or commercialize products before or more successfully.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• Crucial components used in the manufacturing process are acquired from vendors with few alternate sources, risking supply disruption.
• Dependence on key personnel to operate the business, and potential inability to retain, attract, and integrate qualified personnel.
• Failure to comply with environmental, health, and safety laws and regulations could subject the company to fines, penalties, or other costs.
• Business disruptions caused by natural disasters, infrastructure interruptions, or other public health threats.
• Inability to obtain or protect certain intellectual property rights.
• Intellectual property rights may not necessarily address all potential threats to any competitive advantage.
• Technology may be found to infringe upon third-party intellectual property rights.
• Inability to license needed intellectual property from third parties on commercially reasonable terms or at all.
• Harm to business and competitive position if the confidentiality of trade secrets is not protected.
• Share price may be volatile, which could subject the company to securities class action lawsuits.
• Directors, executive officers, and principal shareholders have substantial control over the company (27.0% to 32.8% of outstanding common stock) and could hinder appropriate corporate control.
• Provisions in Canadian charter documents could make an acquisition of the company more difficult.
• Potential classification as a passive foreign investment company (PFIC) for US tax purposes, negatively affecting US investors.
• Governance by corporate laws in British Columbia, Canada, which in some cases have a different effect on shareholders than corporate laws in Delaware, United States.
• Raising additional capital may cause dilution to existing shareholders, restrict operations, or require relinquishing rights to technologies or product candidates.
• Future sales, or the possibility of future sales, of a substantial number of common stock could adversely affect the price and dilute shareholders.
• Limited ability to use some or all of net operating loss and research tax credit carryforwards in the future due to Section 382 of the Internal Revenue Code.
• Failure to maintain an effective system of internal control over financial reporting could cause shareholders to lose confidence in financial reporting or prevent fraud.

Future Outlook

The company expects to incur significant and increasing operating losses for the foreseeable future as it advances its drug candidates through preclinical testing and clinical trials. No revenue is expected in fiscal year 2026. Future dividend payments will be considered at the discretion of the board based on operational circumstances, earnings, cash flow, and financial requirements. The Phase II stroke study for Hutrukin is on hold pending regulatory clarity for the cancer and arthritis programs. The company plans to file investigational new drug applications for its shingles and influenza True Human antibodies in the upcoming year. Current cash and liquid assets are believed to be sufficient for at least the next 12 months.

Management Comments

• "The company believes the findings from the [Natrunix oncology] study represent a potentially transformative approach to cancer management."
• "The company further believes that the treatment effect is not specific to pancreatic cancer, and a similar effect may be seen in other solid tumors being treated with chemotherapy."
• "The Company continues to believe in the potential for Natrunix as a treatment for arthritic diseases."
• "We believe that our employees collective knowledge of our business allows us to operate as among the most cost effective, efficient and capable operations in the biotechnology industry."
• "We believe that our future success is also highly dependent on the contributions of other significant Company personnel, as well as our ability to attract and retain highly skilled and experienced sales, research and development and other personnel in the United States and abroad."
• "We believe that to suggest that such bank account interest makes us a PFIC is absurd; this would suggest that we cannot keep our cash in a bank account and that interest on the Company's funds supersedes any other consideration in defining the actual operations and essential nature of the Company. XBiotech will never accept an arbitrary and erroneous definition that could potentially penalize the Company and its shareholders and will oppose any effort to do so by the tax authorities."
• "Based on our cash and liquid assets, we believe that our cash and liquid assets will provide us with sufficient financial resources to fund operations and meet our capital requirements and anticipated obligations as they become due."
• "The Company expects to have sufficient cash through at least 12 months from the date of this report."

Industry Context

StockSavvy.ai notes that XBiotech operates in the highly competitive biopharmaceutical industry, focusing on a unique "True Human" antibody approach, contrasting with the prevalent animal-derived and engineered antibody therapeutics that dominate the $247 billion market. The company's strategy to develop multiple anti-IL-1a antibodies for different disease indications, allowing for separate partnerships or sales, aligns with broader industry trends of maximizing asset value and diversifying risk, especially given the significant market potential for IL-1a blocking therapies, comparable to anti-TNF therapies. The challenges faced in clinical trials, such as enrollment irregularities and regulatory clarity, are common hurdles in drug development, highlighting the inherent risks in the sector.

Comparison to Industry Standards

• The company's "True Human" antibody approach is unique, as "all other marketed antibody therapeutics are derived from animal immunization."
• The potential unmet medical need for blocking IL-1a is described as "very significant, on the scale of the anti-TNF therapies developed over the past twenty-five years," referencing the success of therapies like Amgen's G-CSF (approved 1991) as an analogous adjunct therapy in cancer.
• The company's R&D and manufacturing center is described as "state-of-the-art," suggesting a high standard of infrastructure.
• The company claims its operations are "among the most cost effective, efficient and capable operations in the biotechnology industry," though no specific comparative metrics are provided.

Management Changes

Corporate Governance

Legal Proceedings

• The Company is not currently subject to any material legal proceedings.

Related Party Transactions

• On January 3, 2024, the company entered into a $10 million convertible loan agreement with John Simard, the Company's Founder, Chairman, and former President and Chief Executive Officer. This loan was fully repaid on January 31, 2025.
• John Simard received a severance payment of $17.3 million and a 2025 annual bonus of $4.5 million upon his retirement as CEO on December 8, 2025.
• John Simard, as Chairman, beneficially owns, with affiliates, at least 27.0% of outstanding common stock, and potentially 32.8% if options are fully exercised, indicating substantial control over the company.

Stakeholder Impact

• **Shareholders**: Increased net loss and significant cash burn could negatively impact share value. Dilution risk from potential future capital raises. Uncertainty regarding the realization of $600 million in potential milestone payments from Janssen. The concentration of ownership by directors, executive officers, and principal shareholders (27.0% to 32.8%) could influence corporate control.
• **Employees**: The company maintains competitive compensation programs (salaries, stock options, bonuses) to attract and retain talent. The transition of the CEO role and the appointment of new board members could affect employee morale and strategic direction.
• **Customers/Patients**: Positive preliminary data from the Natrunix oncology program offers hope for new cancer therapies. However, the halt of the rheumatology program and the hold on the stroke program delay potential treatments for patients in those areas.
• **Creditors**: The full repayment of the $10 million convertible loan to John Simard reduces the company's debt obligations to a related party.
• **Regulatory Authorities**: Ongoing discussions with the FDA for the Natrunix oncology program indicate continued engagement. The company's ability to secure regulatory approvals is critical for its product pipeline.

Next Steps

• Ongoing discussions with the FDA for the future regulatory path of Natrunix in oncology.
• Clarification of regulatory paths for cancer and arthritis programs with the FDA.
• Working towards filing investigational new drug applications for True Human antibodies against shingles and influenza in the upcoming year.
• Potential launch of a Phase II study for Hutrukin in stroke after regulatory clarity for other programs.
• Board of Directors to determine any future cash dividends based on financial condition, results of operations, capital requirements, and other factors.
• Proxy Statement for the 2026 Annual Meeting of Stockholders to be filed by April 28, 2026.
• 2026 Annual Meeting of Stockholders to be held by June 24, 2026.

Key Dates

Recommendation

While XBiotech reported an increased net loss and a significant setback in its rheumatology program, the positive preliminary data from the Natrunix oncology trial and the ongoing regulatory discussions with the FDA present a potential upside. The company's strong cash position for the next 12 months provides some stability, but the lack of product revenue and reliance on future financing warrant caution. The stock is a "hold" for investors monitoring the oncology pipeline's progress and regulatory clarity, but the risks associated with clinical development and market acceptance remain high.

Keywords

Biopharmaceutical, Monoclonal Antibodies, True Human Antibodies, IL-1a, Natrunix, Hutrukin, Oncology, Pancreatic Cancer, Rheumatoid Arthritis, Stroke, Infectious Disease, MRSA, C. difficile, Shingles, Influenza, Clinical Trials, Drug Development, SEC Filing, 10-K, XBiotech, XBIT, Biotechnology, Pharmaceutical, Corporate Governance, Risk Factors, Financial Performance, R&D, FDA, EMA, Intellectual Property